Nothing Special   »   [go: up one dir, main page]

KR20160064496A - Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester - Google Patents

Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester Download PDF

Info

Publication number
KR20160064496A
KR20160064496A KR1020140168158A KR20140168158A KR20160064496A KR 20160064496 A KR20160064496 A KR 20160064496A KR 1020140168158 A KR1020140168158 A KR 1020140168158A KR 20140168158 A KR20140168158 A KR 20140168158A KR 20160064496 A KR20160064496 A KR 20160064496A
Authority
KR
South Korea
Prior art keywords
composition
hydroxy
octadeca
diene
acetic acid
Prior art date
Application number
KR1020140168158A
Other languages
Korean (ko)
Other versions
KR102215168B1 (en
Inventor
박준성
김동현
이옥찬
황경환
홍용덕
Original Assignee
(주)아모레퍼시픽
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by (주)아모레퍼시픽 filed Critical (주)아모레퍼시픽
Priority to KR1020140168158A priority Critical patent/KR102215168B1/en
Publication of KR20160064496A publication Critical patent/KR20160064496A/en
Application granted granted Critical
Publication of KR102215168B1 publication Critical patent/KR102215168B1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/02Preparations for care of the skin for chemically bleaching or whitening the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester and, more specifically, to a composition which shows a significantly excellent whitening effect by using acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester, improves skin pigmentation or deadness of a skin such as chloasmas and freckles and can evenly and brightly show skin tone.

Description

16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 피부 미백용 조성물{Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester}The present invention relates to a composition for skin whitening comprising 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid , 14-diynyl ester}

본 발명은 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하는 미백용 조성물에 관한 것으로서, 보다 구체적으로는 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 사용함으로써 현저하게 우수한 미백 효과를 나타내며, 특히 기미, 주근깨와 같은 색소 침착 증상 또는 피부의 칙칙함을 개선하고, 피부색을 균일하고 밝게 보일 수 있게 하는 조성물에 관한 것이다.
The present invention relates to a whitening composition containing 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, more specifically 16-hydroxy-octadeca- -Diene-12,14-dienyl ester acetic acid, the composition exhibits remarkably excellent whitening effect. In particular, the present invention relates to a composition which improves pigmentation symptoms such as spots and freckles or dullness of the skin and makes the skin color uniform and bright .

사람의 피부색은 멜라닌 색소를 만드는 멜라노사이트(melanocyte)의 활동성, 혈관의 분포, 피부의 두께, 및 카로티노이드, 빌리루빈 등 인체 내외의 색소 함유 유무와 같은 여러 요인들에 의해 결정된다. 특히 멜라노사이트에서 타이로시나제(tyrosinase) 등의 여러 효소가 작용하여 생성되는 멜라닌이라는 흑색 색소가 가장 중요한 요인이다. 멜라닌 색소의 형성에는 유전적 요인, 호르몬 분비, 스트레스 등과 관련된 생리적 요인 및 자외선 조사 등과 같은 환경적 요인이 영향을 미친다. 멜라닌은 피부에 존재하여 자외선 등으로부터 신체를 보호하는 중요한 기능을 하지만 멜라닌이 과잉생산됨으로써 색소침착 및 피부노화를 촉진하고 피부암 유발에도 주요한 작용을 하는 것으로 알려져 있다. 피부색소 이상 침착 증상과 자외선 노출 등에 의해 발생된 과도한 멜라닌 색소 침착을 치료 또는 경감시켜주기 위해서 이전부터 아스코르빈산(ascorbic acid), 코지산(kojic adcid), 알부틴(arbutin), 하이드로퀴논(hudroquinone), 글루타치온(glutathione) 또는 이들의 유도체, 타이로시나제 저해활성을 가진 물질들을 화장료나 의약품에 배합하여 사용해 왔는데, 이들은 불충분한 미백 효과, 피부에 대한 안전성 문제, 및 화장료에 배합시 제형 내에서의 안정성 문제 등으로 인해 그 사용이 제한되고 있다.Human skin color is determined by various factors such as the activity of melanocyte making melanocyte, the distribution of blood vessels, the thickness of skin, and the presence or absence of pigment inside and outside the body, such as carotenoids and bilirubin. The most important factor is melanin, a melanin produced by various enzymes such as tyrosinase in melanocytes. The formation of melanin pigment is affected by environmental factors such as genetic factors, hormonal secretion, physiological factors such as stress, and ultraviolet irradiation. Melanin is present in the skin and protects the body from ultraviolet rays, but it is known that melanin is overproduced, thereby promoting pigmentation and aging of the skin and leading to skin cancer induction. (Ascorbic acid, kojic adcid, arbutin, hudroquinone) have been previously used to treat or relieve excessive melanin pigmentation caused by skin pigmentation abnormalities and ultraviolet exposure. Glutathione or a derivative thereof and a substance having inhibitory activity against tyrosinase have been used in cosmetics or medicines in combination with insufficient whitening effect, safety to the skin, Its use is restricted due to stability problems and so on.

한편, 근래에 천연 소재로부터 분리한 성분의 종류로서, 인삼에서 추출한 성분, 특히 폴리인(polyyne) 성분에 대한 관심이 높아지고 있다. 그 중에서 폴리아세틸렌 성분으로서 파낙시놀, 파낙시돌, 파낙시트리올 등에 대하여는 암세포에 대한 세포 독성을 가지고 있어 항암 효과가 있음이 밝혀지고 있다. 그러나, 아직 폴리아세틸렌 성분에 대한 연구는 미미하며, 특히 항암 효과 이외에 피부 상태 개선 등과 관련하여 나타내는 효능에 대해서는 주목할 만한 연구성과가 보고된 바 없다.
On the other hand, interest in the components extracted from ginseng, particularly polyyne, has been increasing as a component separated from natural materials in recent years. Among them, paracinol, paraxidol, paraxyltriol and the like as polyacetylene components have cytotoxicity against cancer cells and thus have anticancer effects. However, the research on the polyacetylene component is still insignificant, and remarkable research results have not been reported on the efficacy shown in relation to the skin condition improvement other than the anticancer effect.

한국 공개특허 10-2012-0083943호(2012년 7월 27일 공개)Korean Patent Laid-Open No. 10-2012-0083943 (published on July 27, 2012)

이에 본 발명자들은 우수한 피부 미백 효과 등을 나타내는 물질을 찾고자 연구하던 중, 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산이 우수한 피부 미백 효과를 제공할 수 있으면서 피부에 대한 자극은 작음을 발견하고 본 발명을 완성하게 되었다.Accordingly, the present inventors searched for a substance showing excellent skin whitening effect and the like, and found that 16-hydroxy-octadeca-9,17-dien-12,14-dienyl ester acetic acid can provide excellent skin whitening effect The stimulation on the skin was found to be small, and the present invention was completed.

따라서, 본 발명은 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 사용함으로써 우수한 피부 미백 효과를 나타내는 조성물을 제공하는 것을 목적으로 한다.
Accordingly, it is an object of the present invention to provide a composition exhibiting excellent skin whitening effect by using 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid.

상기한 목적을 달성하기 위하여, 본 발명은 하기 화학식 1로 표현되는 화합물인 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 유효성분으로 함유하는 미백용 피부 외용제 조성물 또는 약학 조성물을 제공한다.In order to attain the above object, the present invention provides a whitening skin containing 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, which is a compound represented by the following general formula An external application composition or a pharmaceutical composition.

Figure pat00001
Figure pat00001

본 발명의 조성물은 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유함으로써 우수한 피부 미백 효과를 제공하여 기미, 주근깨와 같은 색소 침착 증상을 감소시키고, 피부 칙칙함을 개선시키며, 피부색을 균일하고 밝게 보일 수 있게 한다.
The composition of the present invention provides excellent skin whitening effect by containing 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, thereby reducing pigmentation symptoms such as spots and freckles, It improves dullness and makes skin color look uniform and bright.

본 발명의 조성물은 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산(acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester)을 유효성분으로 함유하여, 우수한 피부 미백 효과를 제공한다.The composition of the present invention comprises 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid 16-hydroxy-octadeca-9,17-diene-12,14- As an active ingredient, and provides an excellent skin whitening effect.

본 발명에서 사용되는 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산은 아세테이트는 하기 화학식 1의 구조를 가지는 화합물로서, 분자량은 316이고, (Z)-16-하이드록시-9,17-옥타데카디엔-12,14-디이닐 아세테이트((Z)-16-hydroxy-9,17-octadecadiene-12,14-diynyl acetate)라고도 한다.The 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid acetate used in the present invention has a molecular weight of 316 and a (Z) -16 -Dihydroxy-9,17-octadecadiene-12,14-diynyl acetate) is also referred to as hydroxy-9,17-octadecadien-12,14-dienyl acetate ((Z) -16-hydroxy-9,17-octadecadiene-12,14-diynyl acetate).

[화학식 1][Chemical Formula 1]

Figure pat00002
Figure pat00002

본 발명에 의한 조성물은 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 조성물 총 중량에 대하여 0.001~50중량%, 바람직하게는 0.01~30 중량%, 보다 바람직하게는 0.1~10% 중량%의 양으로 함유할 수 있다. 상기 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산의 함량이 0.001중량% 미만이면 상기 성분에 의한 효능, 효과가 미약하고, 50중량%를 초과하면 피부 안전성 또는 제형상의 문제가 있기 때문이다.The composition according to the present invention may contain 0.001 to 50% by weight, preferably 0.01 to 30% by weight, based on the total weight of the composition, of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid By weight, preferably 0.1 to 10% by weight. If the content of the 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid is less than 0.001% by weight, Or there is a problem of the shape.

본 발명의 조성물은 피부 외용제 조성물, 특히 화장료 조성물로서 제형화될 수 있으며, 화장품학 또는 피부과학적으로 허용 가능한 매질 또는 기제를 함유하여 제형화될 수 있다. 또한, 본 발명의 조성물은 국소 적용에 적합한 모든 제형으로 제공될 수 있으며, 예를 들어 용액, 수상에 유상을 분산시켜 얻은 에멀젼, 유상에 수상을 분산시켜 얻은 에멀젼, 현탁액, 고체, 겔, 분말, 페이스트, 포말(foam) 또는 에어로졸 조성물의 제형으로 제공될 수 있다. 구체적으로 본 발명의 조성물은 크림, 스킨, 로션, 파우더, 연고, 스프레이 또는 콘실 스틱의 형태로 제공될 수 있다. 이러한 제형의 조성물은 당해 분야의 통상적인 방법에 따라 제조될 수 있다.The composition of the present invention may be formulated as an external preparation for skin, in particular as a cosmetic composition, and may be formulated containing a cosmetically or dermatologically acceptable medium or base. In addition, the composition of the present invention may be provided in any form suitable for topical application, for example, as a solution, an emulsion obtained by dispersing an oil phase in water phase, an emulsion obtained by dispersing water phase in water phase, a suspension, a solid, a gel, Pastes, foams, or aerosol compositions. Specifically, the composition of the present invention may be provided in the form of a cream, a skin, a lotion, a powder, an ointment, a spray or a cone stick. Compositions of such formulations may be prepared according to conventional methods in the art.

또한, 본 발명에 따른 조성물은 상기한 물질 이외에 주 효과를 손상시키지 않는 범위 내에서, 바람직하게는 주 효과에 상승 효과를 줄 수 있는 다른 성분들을 포함할 수 있다. 또한 본 발명에 따른 조성물은 보습제, 에몰리언트제, 자외선 흡수제, 방부제, 살균제, 산화 방지제, pH 조정제, 유기 및 무기 안료, 향료, 냉감제 또는 제한제를 더 포함할 수 있다. 상기 성분의 배합량은 본 발명의 목적 및 효과를 손상시키지 않는 범위 내에서 당업자가 용이하게 선정 가능하며, 그 배합량은 조성물 총 중량에 대하여 0.01~5중량%, 구체적으로 0.01~3중량%일 수 있다.In addition, the composition according to the present invention may contain, in addition to the above-mentioned substances, other ingredients which can give a synergistic effect to the main effect, to the extent that the main effect is not impaired. The composition according to the present invention may further comprise a humectant, an emollient, an ultraviolet absorber, an antiseptic, a bactericide, an antioxidant, a pH adjuster, an organic or inorganic pigment, a perfume, a cold agent or a limiting agent. The compounding amount of the above components can be easily selected by a person skilled in the art within the range not impairing the object and effect of the present invention, and the amount thereof may be from 0.01 to 5% by weight, specifically from 0.01 to 3% by weight based on the total weight of the composition .

또한, 본 발명의 조성물은 약학 조성물로서 제형화될 수 있다. 본 발명에 따른 조성물을 의약품에 적용할 경우에는, 본 발명에서 사용되는 유효성분에 상용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 경구 투여제 혹은 비경구 투여제로 제형화할 수 있으며, 본 발명에 따른 상기 약학 조성물은 경구, 비경구, 직장, 국소, 경피, 정맥 내, 근육 내, 복강 내, 피하 등으로 투여될 수 있다. In addition, the composition of the present invention can be formulated as a pharmaceutical composition. When the composition according to the present invention is applied to medicines, it may be formulated into oral, parenteral or parenteral dosage forms in solid, semi-solid or liquid form by adding an inorganic or organic carrier compatible with the active ingredient used in the present invention , The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously, and the like.

상기 경구 투여를 위한 제형으로서는 정제, 환제, 과립제, 캡슐제, 산제, 세립제, 분제, 유탁제, 시럽제, 펠렛제 등을 들 수 있다. 또한, 상기 비경구 투여를 위한 제형으로는 주사제, 점적제, 연고, 로션, 스프레이, 현탁제, 유제, 좌제 등을 들 수 있다. 본 발명에 따른 조성물은 상법에 따라 실시함으로써, 유효성분을 용이하게 제형화할 수 있으며, 이 때 계면활성제, 부형제, 착색료, 향신료, 보존료, 안정제, 완충제, 현탁제, 기타 상용하는 보조제를 적당히 사용할 수 있다.Examples of the formulations for oral administration include tablets, pills, granules, capsules, powders, fine granules, powders, emulsions, syrups and pellets. In addition, the formulations for parenteral administration include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. The composition according to the present invention can be easily formulated into an active ingredient by carrying out the composition according to a conventional method. In this case, a surfactant, excipient, coloring agent, spice, preservative, stabilizer, buffer, suspending agent, have.

본 발명의 약학 조성물의 유효 성분의 투여 용량은 투여받을 대상의 연령, 성별, 체중, 병리 상태 및 그 심각도, 투여 경로 또는 처방자의 판단에 따라 달라질 것이다. 이러한 인자에 기초한 적당한 용량의 결정은 당업자의 수준 내에 있으며, 이의 1일 투여 용량은 예를 들어 0.1mg/kg/일 내지 100mg/kg/일, 보다 구체적으로는 5mg/kg/일 내지 50mg/kg/일이 될 수 있으나, 이에 제한되는 것은 아니다.
The dosage of the active ingredient of the pharmaceutical composition of the present invention will vary depending on the age, sex, body weight, pathological condition and severity of the subject to be treated, route of administration, or judgment of the prescriber. Determination of the appropriate dose based on these factors is well within the level of ordinary skill in the art and its daily dose is, for example, from 0.1 mg / kg / day to 100 mg / kg / day, more specifically from 5 mg / kg / day to 50 mg / / Day, but is not limited thereto.

이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.

[참고예 1][Referential Example 1]

본 발명의 조성물의 효능을 실험하기 위한 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산은 ㈜코스비전(한국)으로부터 구입하여 사용하였다.
The 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid used to test the efficacy of the composition of the present invention was purchased from Cosvision (Korea).

[시험예 1] 티로시나제 저해 효과Test Example 1: Effect of tyrosinase inhibition

티로시나제 효소는 버섯류(Mushroom)로부터 추출된 것으로 시그마(SIGMA)사의 것을 사용하였다. 먼저 기질인 티로신을 증류수에 용해시켜 0.3mg/ml의 용액으로 만들고 그 용액을 1.0ml씩 시험관에 넣은 다음, 여기에 포타슘-포스페이트 완충용액(0.1mol 농도, pH 6.8) 1.0ml 및 증류수 0.7ml를 첨가하였다.The tyrosinase enzyme was extracted from Mushroom and was obtained from Sigma. First, the substrate, tyrosine, is dissolved in distilled water to make a 0.3 mg / ml solution. The solution is put into a test tube in an amount of 1.0 ml. Then, 1.0 ml of potassium phosphate buffer solution (0.1 mol concentration, pH 6.8) and 0.7 ml of distilled water .

상기 참고예 1의 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 에탄올 용액에 적당한 농도로 혼합하여 준비한 시료액 0.2ml를 반응액에 넣은 다음 37℃ 항온조에서 10분 동안 반응시켰다. 이때 음성대조군(무첨가)으로는 시료액 대신 용매만을 0.2ml 넣은 것으로 준비하였고, 양성대조군으로는 아스코르브산을 사용하였다. 이 반응액에 2500유닛/ml의 티로시나제 용액 0.1ml씩을 넣고 다시 37℃ 항온조에서 10분 동안 반응시켰다. 이 반응액이 든 시험관을 얼음물 속에 넣어서 급냉시켜 반응을 중지시키고 광전분광분석계로 파장 475nm에서의 흡광도를 측정하였으며, 그 결과를 하기 표 1에 나타내었다. 각각의 티로시나제 저해 효과는 하기 수학식 1로 산출하였다.A solution of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid of Reference Example 1 in an appropriate concentration was added to 0.2 ml of the sample solution, Lt; / RTI > for 10 minutes. As a negative control, 0.2 ml of a solvent was used instead of the sample solution, and ascorbic acid was used as a positive control. 0.1 ml of tyrosinase solution of 2500 units / ml was added to the reaction solution, followed by reaction at 37 ° C for 10 minutes. The reaction tube was immersed in ice water to quench the reaction, and the absorbance at 475 nm was measured with a photoelectron spectrometer. The results are shown in Table 1 below. Each tyrosinase inhibitory effect was calculated by the following equation (1).

Figure pat00003
Figure pat00003

시험물질Test substance 티로시나제 저해율(%)Inhibition rate of tyrosinase (%) 대조군(무첨가)Control group (no addition) 00 아스코르브산Ascorbic acid 5252 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 3636

상기 표 1의 결과에서, 본 발명에서 사용되는 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산의 티로시나제 억제율이 우수함을 확인할 수 있다.
From the results of Table 1, it can be confirmed that the inhibition rate of tyrosinase of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid used in the present invention is excellent.

[시험예 2] B16/F10 멜라노마 세포를 이용한 멜라닌 생성 억제 효과[Test Example 2] Inhibitory effect on melanin formation by B16 / F10 melanoma cells

본 시험예에 사용된 B16/F10 멜라노마는 마우스에서 유래한 세포주이며, 멜라닌이라는 흑색색소를 분비하는 세포의 악성화로 생긴 암세포이다. 이 세포의 인공 배양 중에 시험물질을 처리하여 멜라닌 생성이 감소하는 정도를 비교 평가 하였다. 본 시험예에서 사용된 B16/F10 멜라노마는 한국세포주은행(KCLB No: 8008)으로부터 분양받아 사용하였다.The B16 / F10 melanoma used in this test example is a mouse-derived cell line, and is a cancer cell caused by malignant cell which secretes a melanin pigment called melanin. During the artificial incubation of these cells, the test material was treated to compare the degree of decrease in melanin production. The B16 / F10 melanoma used in this test was purchased from Korean Cell Line Bank (KCLB No: 8008).

B16/F10 멜라노마의 멜라닌 생합성 억제효과 측정은 다음과 같이 행하였다. B16/F10 멜라노마를 6 웰 플레이트에 5×105/웰로 분주하여 37℃, 5% CO2 배양기(MCO-20AIC, Sanyo)에서 약 24시간동안 10% FBS(fetal bovine serum)를 함유한 DMEM(Dulbecco's Modified Eagle's Medium)에서 배양하였다. FBS가 없는 새로운 DMEM 배지에 시험물질로서 상기 참고예 1의 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 0.1중량%로 첨가하고 72시간 경과시켰다. 트립신-EDTA를 처리하고 원심분리하여 세포를 분리한 후, DMSO를 함유한 1N NaOH를 이용해 95℃에서 멜라닌을 용해하였다. ELISA 리더(DIbiotech, Korea)를 활용하여 405nm에서 흡광도를 측정하였다. 시험물질을 첨가하지 않은 세포를 대조군으로 하여 대조군에서의 멜라닌 함량과 비교하여 각 시험물질의 멜라닌 생성 저해 정도를 측정하였다. 수학식 2에 따라 멜라닌 생성 억제율을 계산하여 그 결과를 표 2에 나타내었다.Melanin biosynthesis inhibitory effect of B16 / F10 melanoma was measured as follows. B16 / F10 melanoma cells were seeded in a 6-well plate at 5 × 10 5 cells / well and cultured in DMEM containing 10% FBS (fetal bovine serum) for 24 hours in a 5% CO 2 incubator (MCO-20AIC, Dulbecco ' s Modified Eagle ' s Medium). To the new DMEM medium without FBS, 0.1% by weight of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid of Reference Example 1 was added as a test substance and aged for 72 hours. After treatment with trypsin-EDTA, the cells were separated by centrifugation, and melanin was dissolved at 95 ° C in 1N NaOH containing DMSO. Absorbance was measured at 405 nm using an ELISA reader (DIbiotech, Korea). Cells to which the test substance was not added were used as a control group, and the melanin formation inhibition degree of each test substance was measured by comparing with the melanin content in the control group. The inhibition rate of melanin production was calculated according to Equation (2), and the results are shown in Table 2.

Figure pat00004
Figure pat00004

시험물질Test substance 멜라닌생성 저해율(%)Melanin inhibition rate (%) 대조군(무첨가)Control group (no addition) 00 코지산Kojic acid 5353 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 3636

상기 표 2의 결과에서, 본 발명에서 사용되는 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산의 멜라닌 생성 억제율이 우수함을 확인할 수 있다.
From the results shown in Table 2, it can be confirmed that the inhibitory rate of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid used in the present invention is excellent.

[제형예 1 및 비교제형예 1][Formulation Example 1 and Comparative Formulation Example 1]

하기 표 3의 조성에 따라 통상적인 방법으로 영양크림을 제조하였다(단위: 중량%).Nutritive creams were prepared in a conventional manner according to the composition of Table 3 below (unit: wt%).

배합성분Compounding ingredient 제형예 1Formulation Example 1 비교제형예 1Comparative Formulation Example 1 정제수Purified water To 100To 100 To 100To 100 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 0.10.1 -- 식물성 경화유Vegetable hydrogenated oil 1.501.50 1.501.50 스테아린산Stearic acid 0.600.60 0.600.60 글리세롤 스테아레이트Glycerol stearate 1.001.00 1.001.00 스테아릴 알코올Stearyl alcohol 2.002.00 2.002.00 폴리글리세릴-10 펜타스테아레이트 & 베헤닐 알코올 &소디움 스테아로일 락틸에이트Polyglyceryl-10pentastearate and behenyl alcohol and sodium stearoyl lactylate 1.001.00 1.001.00 아라키딜 베헤닐 알코올 &아라키딜글루코사이드Arachidyl behenyl alcohol and arachidyl glucoside 1.001.00 1.001.00 세틸아릴 알코올 & 세테아릴글루코사이드Cetylaryl Alcohol and Cetearyl Glucoside 2.002.00 2.002.00 PEG-100 스테아레이트 & 글리세롤올레이트 & 프로필렌글리콜PEG-100 Stearate & Glycerololate & Propylene Glycol 1.501.50 1.501.50 카프릴릭/카르릭 트리 글리세라이드Caprylic / carboxy triglyceride 11.0011.00 11.0011.00 사이클로메디콘Cyclomedicone 6.006.00 6.006.00 방부제, 향Preservative, incense 적량Suitable amount 적량Suitable amount 트리에탄올 아민Triethanolamine 0.10.1 0.10.1

[시험예 3] 피부톤 개선 효과[Test Example 3] Skin tone improvement effect

16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산의 피부톤 개선 효과를 알아보기 위하여 20명의 피험자를 10명씩 2개 군으로 나누고 각 군의 피험자에게 상기 제형예 1 및 비교제형예 1을 각각 사용(저녁 1회/일 도포, 총 1주간)하도록 한 후, Facial Stage DM-3(Moritex, Japan) 기기를 활용하여 피부톤 개선 정도를 평가하였다. 피부톤 개선율은 피부의 명도 및 색채 측정값으로부터 피부의 명도 및 색채 변화 값을 구하여 판단하였으며, 그 결과의 평균값을 구하여 하기 표 4에 나타내었다. 명도 및 색체 변화값이 클수록 피부톤이 개선되었음을 의미한다.To examine the effect of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid on improving skin tone, 20 subjects were divided into two groups of 10 persons each, And Comparative Formulation Example 1 were used (once a day / once a day for a total of one week), and the degree of skin tone improvement was evaluated using a Facial Stage DM-3 (Moritex, Japan) apparatus. The skin tone improvement rate was determined by determining the brightness and color change values of the skin from the lightness and color measurement values of the skin, and the average value of the results was obtained. The larger the value of brightness and color change, the better the skin tone.

시험물질Test substance 피부톤 개선율(%)Skin tone improvement rate (%) 명도brightness 색채Color 제형예 1Formulation Example 1 1313 1212 비교제형예 1Comparative Formulation Example 1 1010 99

표 4의 결과를 보면, 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 함유하지 않는 비교제형예 1은 유의적인 피부톤 개선 효능을 보이지 않은 반면, 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 유효성분으로 함유하는 제형예 1은 사용전보다 사용후의 피부톤이 많이 개선되는 것을 확인할 수 있다.
The results in Table 4 show that Comparative Formulation Example 1, which does not contain 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, It can be confirmed that Formulation Example 1 containing hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid as an active ingredient has much improved skin tone after use than before use.

[제제예 1] 화장수[Formulation Example 1] Lotion

아래 표 5에 기재된 조성으로 통상의 방법에 따라 화장수를 제조한다.Lotions are prepared according to a conventional method with the composition shown in Table 5 below.

함량(중량%)Content (% by weight) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 2.02.0 글리세린glycerin 3.03.0 부틸렌글리콜Butylene glycol 2.02.0 프로필렌글리콜Propylene glycol 2.02.0 카르복시비닐폴리머Carboxyvinyl polymer 0.10.1 PEG 12 노닐페닐에테르PEG 12 nonyl phenyl ether 0.20.2 폴리솔베이트 80Polysorbate 80 0.40.4 에탄올ethanol 10.010.0 트리에탄올아민Triethanolamine 0.10.1 방부제, 색소, 향료Preservative, coloring, fragrance 적량Suitable amount 정제수Purified water 잔량Balance

[제제예 2] 영양 크림[Formulation Example 2] Nourishing cream

아래 표 6에 기재된 조성으로 통상의 방법에 따라 영양 크림을 제조한다.Nutrition cream is prepared according to the conventional method with the composition shown in Table 6 below.

함량(중량%)Content (% by weight) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 2.02.0 폴리솔베이트 60Polysorbate 60 1.51.5 솔비탄세스퀴올리에이트Sorbitan sesquioleate 0.50.5 PEG 60 경화피마자유 PEG 60 hardened castor oil 2.02.0 유동파라핀Liquid paraffin 10.010.0 스쿠알란Squalane 5.05.0 카프릴릭/카프락트리글리세라이드Caprylic / caproic triglyceride 5.05.0 글리세린glycerin 5.05.0 부틸렌글리콜Butylene glycol 3.03.0 프로필렌글리콜Propylene glycol 3.03.0 트리에탄올아민Triethanolamine 0.20.2 방부제, 색소, 향료Preservative, coloring, fragrance 적량Suitable amount 정제수Purified water 잔량Balance

[제제예 3] 마사지 크림[Formulation Example 3] Massage cream

아래 표 7에 기재된 조성으로 통상의 방법에 따라 마사지 크림을 제조한다.A massage cream is prepared according to a conventional method with the composition shown in Table 7 below.

함량(중량%)Content (% by weight) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 1.01.0 밀납Wax 10.010.0 폴리솔베이트 60Polysorbate 60 1.51.5 PEG 60 경화피마자유PEG 60 hardened castor oil 2.02.0 솔비탄세스퀴올레이트Sorbitan sesquioleate 0.80.8 유동파라핀Liquid paraffin 40.040.0 스쿠알란Squalane 5.05.0 카프릴릭/카프릭트리글리세라이드Caprylic / capric triglyceride 4.04.0 글리세린glycerin 5.05.0 부틸렌글리콜Butylene glycol 3.03.0 프로필렌글리콜Propylene glycol 3.03.0 트리에탄올아민Triethanolamine 0.20.2 방부제, 색소, 향료Preservative, coloring, fragrance 적량Suitable amount 정제수Purified water 잔량Balance

[제제예 4] 팩[Formulation Example 4] Pack

아래 표 8에 기재된 조성으로 통상의 방법에 따라 팩을 제조한다.A pack is prepared according to a conventional method with the composition shown in Table 8 below.

함량(중량%)Content (% by weight) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 1.01.0 폴리비닐알콜Polyvinyl alcohol 13.013.0 소듐카르복시메틸셀룰로오스Sodium carboxymethylcellulose 0.20.2 글리세린glycerin 5.05.0 알란토인Allantoin 0.10.1 에탄올ethanol 6.06.0 PEG 12 노닐페닐에테르PEG 12 nonyl phenyl ether 0.30.3 폴리솔베이트 60Polysorbate 60 0.30.3 방부제, 색소, 향료Preservative, coloring, fragrance 적량Suitable amount 정제수Purified water 잔량Balance

[제제예 5] 젤[Formulation Example 5] Gel

아래 표 9에 기재된 조성으로 통상의 방법에 따라 젤을 제조한다.A gel is prepared according to a conventional method with the composition shown in Table 9 below.

함량(중량%)Content (% by weight) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 0.50.5 에틸렌디아민초산나트륨Ethylenediamine sodium acetate 0.050.05 글리세린glycerin 5.05.0 카르복시비닐폴리머Carboxyvinyl polymer 0.30.3 에탄올ethanol 5.05.0 PEG 60 경화피마자유PEG 60 hardened castor oil 0.50.5 트리에탄올아민Triethanolamine 0.30.3 방부제, 색소, 향료Preservative, coloring, fragrance 적량Suitable amount 정제수Purified water 잔량Balance

[제제예 6] 연고[Formulation Example 6] Ointment

아래 표 10에 기재된 조성으로 통상적인 방법으로 연고를 제조하였다.Ointments were prepared in a conventional manner with the compositions shown in Table 10 below.

함량(중량%)Content (% by weight) 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester Acetic acid 0.10.1 글리세린glycerin 8.08.0 부틸렌글리콜Butylene glycol 4.04.0 유동파라핀Liquid paraffin 15.015.0 베타글루칸Beta Glucan 7.07.0 카보머Carbomer 0.10.1 카프릴릭/카프릭 트리글리세라이드Caprylic / capric triglyceride 3.03.0 스쿠알란Squalane 1.01.0 세테아릴 글루코사이드Cetearyl glucoside 1.51.5 소르비탄 스테아레이트Sorbitan stearate 0.40.4 세테아릴 알코올Cetearyl alcohol 1.01.0 밀납Wax 4.04.0 방부제, 색소, 향료Preservative, coloring, fragrance 적량Suitable amount 정제수Purified water 잔량Balance

[제제예 7] 연질캅셀제[Formulation Example 7] Soft capsule

16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산 0.0025g, 비타민 C 0.0025g, 팜유 2mg, 팜경화유 8mg, 황납 4mg 및 레시틴 6mg을 혼합하고, 통상의 방법에 따라 1 캡슐당 400 mg씩 충진하여 연질캅셀을 제조하였다.
0.0025 g of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, 0.0025 g of vitamin C, 2 mg of palm oil, 8 mg of palm kernel oil, 4 mg of yellowpowder and 6 mg of lecithin were mixed, 400 mg / capsule was filled to prepare a soft capsule.

[제제예 8] 정제[Formulation Example 8] Tablets

16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산 0.0025g, 비타민 C 0.0025g, 포도당 100mg, 전분 96mg 및 마그네슘 스테아레이트 4mg을 혼합하고 30% 에탄올을 40mg 첨가하여 과립을 형성한 후, 60℃에서 건조하고 타정기를 이용하여 정제로 타정하였다.
0.0025 g of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, 0.0025 g of vitamin C, 100 mg of glucose, 96 mg of starch and 4 mg of magnesium stearate were mixed and 40 mg of 30% After granules were formed, they were dried at 60 DEG C and tableted using a tablet machine.

[제제예 9] 과립제[Formulation Example 9]

16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산 150mg, 비타민 C 150mg, 포도당 100mg, 및 전분 600mg을 혼합하고 30% 에탄올을 100 mg 첨가하여 과립을 형성한 후, 60℃에서 건조하여 과립을 형성한 다음 포에 충진하였다. 내용물의 최종 중량은 1 g으로 하였다.
150 mg of vitamin C, 100 mg of glucose, and 600 mg of starch were mixed and 100 mg of 30% ethanol was added to form granules , And dried at 60 DEG C to form granules, which were filled in a capsule. The final weight of the contents was 1 g.

[제제예 10] 드링크제[Formulation Example 10]

16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산 0.0025g, 비타민 C 0.0025g, 포도당 10g, 구연산 2g 및 정제수 187.8g을 혼합하고 병에 충진하였다. 내용물의 최종 용량은 200ml로 하였다.
0.0025 g of 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid, 0.0025 g of vitamin C, 10 g of glucose, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.

이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적 기술은 단지 바람직한 실시태양일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백할 것이다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다고 할 것이다.
While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.

Claims (4)

하기 화학식 1로 표현되는 16-하이드록시-옥타데카-9,17-디엔-12,14-디이닐 에스테르 아세트산을 유효성분으로 함유하는 미백용 피부 외용제 조성물.
[화학식 1]
Figure pat00005
A composition for external application for skin for whitening skin comprising 16-hydroxy-octadeca-9,17-diene-12,14-dienyl ester acetic acid represented by the following formula 1 as an active ingredient.
[Chemical Formula 1]
Figure pat00005
제1항에 있어서, 상기 유효성분은 조성물 총 중량에 대하여 0.001~50중량%의 양으로 함유되는 피부 외용제 조성물.The composition for external application for skin according to claim 1, wherein the active ingredient is contained in an amount of 0.001 to 50% by weight based on the total weight of the composition. 제1항에 있어서, 상기 조성물은 혈색 및 피부톤 개선용임을 특징으로 하는 피부 외용제 조성물.The composition for external application for skin according to claim 1, wherein the composition is for improving color and skin tone. 제1항에 있어서, 상기 조성물은 화장료 조성물임을 특징으로 하는 피부 외용제 조성물.The composition for external application for skin according to claim 1, wherein the composition is a cosmetic composition.
KR1020140168158A 2014-11-28 2014-11-28 Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester KR102215168B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020140168158A KR102215168B1 (en) 2014-11-28 2014-11-28 Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140168158A KR102215168B1 (en) 2014-11-28 2014-11-28 Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester

Publications (2)

Publication Number Publication Date
KR20160064496A true KR20160064496A (en) 2016-06-08
KR102215168B1 KR102215168B1 (en) 2021-02-16

Family

ID=56193500

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020140168158A KR102215168B1 (en) 2014-11-28 2014-11-28 Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester

Country Status (1)

Country Link
KR (1) KR102215168B1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120083943A (en) 2010-08-13 2012-07-27 (주)아모레퍼시픽 Composition of skin external application containing propanoid derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120083943A (en) 2010-08-13 2012-07-27 (주)아모레퍼시픽 Composition of skin external application containing propanoid derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Bo-Young Park 외 7명, "Isolation and anticomplement activity of compounds from Dendropanax morbifera", J Ethnopharmacol., Vol. 90, No. 2-3, pp. 403-408, Feb 2004. *
Guang-Hua Xu 외 5명, "Polyacetylenes from the Tissue Cultured Adventitious Roots of Panax ginseng C.A. Meyer", Natural Product Sciences, Vol. 14, No. 3, pp. 177-181, Sep 2008. *
Guang-Hua Xu 외 5명, "Polyacetylenes from the Tissue Cultured Adventitious Roots of PanaxAkio Kobayashi 외 2명, "Synth ginseng C.A. Meyer", Natural Product Sciences, Vol. 14, No. 3, pp. 177-181, Sep 2008. *
박수아 외 4명, "Tyrosinase 및 TRP-2의 발현 억제를 통한 황칠나무 잎 추출물의 Melanin 생성 저해 효과", Appl. Chem. Eng., Vol. 25, No. 5, pp. 468-473, October 2014. *

Also Published As

Publication number Publication date
KR102215168B1 (en) 2021-02-16

Similar Documents

Publication Publication Date Title
KR20160023310A (en) Composition for anti-aging containing youngia denticulata extract
KR101736981B1 (en) Compositions containing extracts of glycine gracilis
KR102039608B1 (en) Composition including midodrine and its uses
KR20160066186A (en) Composition for moisturizing the skin containing picrionoside A
KR102163882B1 (en) Composition for skin whitening containing Panax ginseng extract and Green tea extract
KR102215168B1 (en) Composition for skin whitening containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester
KR102215160B1 (en) Composition for skin whitening containing panaxydiol
KR102286684B1 (en) Composition for skin whitening containing (2S)-1-O-linoleoyl-3-O-β-D-galactopyranosyl-sn-glycerol
KR102286683B1 (en) Composition for skin whitening containing (2S)-1-O-linolenoyl-3-O-β-D-galactopyranosyl-sn-glycerol
KR102298803B1 (en) Composition for moisturizing the skin containing (2S)-1-O-linolenoyl-2-O-linolenoyl-3-O-β-D-galactopyranosyl-sn-glycerol
KR102298801B1 (en) Composition for moisturizing the skin containing (2S)-1-O-linolenoyl-3-O-β-D-galactopyranosyl-sn-glycerol
KR20160066729A (en) COMPOSITION FOR SKIN WHITENING CONTAINING (2S)-1-O-7(Z),10(Z),13(Z)-HEXADECATRIENOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL
KR20160067427A (en) COMPOSITION FOR SKIN WHITENING CONTAINING (2S)-1-O-LINOLENOYL-2-O-LINOLENOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL
KR20160067430A (en) COMPOSITION FOR SKIN WHITENING CONTAINING (2S)-1-O-LINOLEOYL-2-O-LINOLEOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL
KR20160081160A (en) Skin external composition for moisturizing or whitening the skin comprising compound K and panaxydol
KR20160081165A (en) Skin external composition for moisturizing or whitening the skin comprising compound K and picrionoside A
KR20160081163A (en) Skin external composition for moisturizing or whitening the skin comprising compound K and icariside B2
KR20160081161A (en) Skin external composition for moisturizing or whitening the skin comprising compound K and acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester
KR20160082115A (en) SKIN EXTERNAL COMPOSITION FOR MOISTURIZING OR WHITENING THE SKIN COMPRISING COMPOUND K AND (2S)-1-O-LINOLENOYL-3-O-β-D-GALACTOPYRANOSYL-SN-GLYCEROL
KR20150030092A (en) Composition for skin whitening containing Panax ginseng polysaccharides and Green tea polysaccharides
KR102215170B1 (en) Composition for moisturizing the skin containing acetic acid 16-hydroxy-octadeca-9,17-diene-12,14-diynyl ester
KR20160081164A (en) Skin external composition for anti-anging comprising compound K and picrionoside A
KR20160082113A (en) Skin external composition for anti-anging comprising compound K and panaxydol
KR102286680B1 (en) Composition for moisturizing the skin containing panaxydol
KR102298802B1 (en) Composition for moisturizing the skin containing (2S)-1-O-linoleoyl-3-O-β-D-galactopyranosyl-sn-glycerol

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant